Dear New World Investor:
This is our next-to-last light week this quarter – the earnings deluge starts the week of July 24.
The Radar Report is published on Thursdays. On Fridays, I repurpose parts of it in two Substack newsletters. Each has a free section and a paywalled portfolio. I mention this because some Lifetime subscribers have decided to subscribe to one or both newsletters.
Boomberg, nominally written by the champion rodeo bull Red Rock, uses some of the first part of the Radar Report in the free section, and then has a portfolio behind the paywall designed for “Tracking the Secular Bull Market to 2036.” There is quite a bit of overlap with the recommendations here, including AAPL, META, SFTBY, ENVX, RKLB, VLD, GILD, NVTA, EQT, FCX, SAND, and GBTC. You will see updates and analysis on these here first, unless one has news on a Friday (which rarely happens). That portfolio also includes five other Big Tech recommendations.
Biotech Moonshots begins with a free section on any facet of the industry – technology, valuation, mergers,news, whatever. The portfolio is behind a paywall and all the stocks are covered here – AKBA, APTO, ARTH, GRPH, INO, NVTA, MDNA, and SCYX. Again, you will see updates and analysis on these here first, unless one has news on a Friday.
* * * * *
Last Friday’s June nonfarm payrolls report showed 209,000 new jobs versus the 225,000 consensus forecast. It was the first time in 15 months that nonfarm payrolls have come in lower than Wall Street expected. But it is subject to some big revisions. The May number was lowered from 339,000 to 306,000 jobs.
Wells Fargo’s economists said: “Today’s employment report offered additional evidence that the labor market is slowly coming into better balance as job growth slows and labor supply steadily expands. That said, job growth of +200K is still quite strong even if it is directionally slower than the scorching pace seen over the past year.”
But was it really over 200,000? April’s job gains were revised lower by a whopping 77,000, from 294,000 to 217,000. So not only does job growth lag what is happening in the economy, the first reported number is – what’s the right word? – oh, yeah, crap. But it still moves markets.
Yesterday’s headline year-over-year June Consumer Price Index came in at +2.97%, the lowest level since March 2021, versus +4.0% in May and just below the consensus estimate for +3.1%. The major difference from June 2022’s +9.2% was oil prices, down from ~$120 to ~$70. I expect that to reverse going forward, but be more than offset by an actual deflation in shelter costs.
The month-over-month rate was +0.2%, below the +0.3% consensus but an uptick from May’s +0.1%. Shelter accounted for over 70% of the month-over-month increase in June. But it already is slowing; it was +0.6% in May, month-over-month, and just +0.4% in June.
Click for larger graphic h/t @JosephPolitano
As I’ve mentioned many times, the shelter numbers lag reality by six to nine months. We are going to see very low shelter growth or even deflation over the rest of the year.
Click for larger graphic h/t @JosephPolitano
The year-over-year Core CPI, which excludes food and energy, was +4.8% in June, down from +5.3% in May and below the 5.0% estimate. It was the lowest reading since October 2021. The month-over-month Core CPI was only +0.16%, the lowest since February 2021 and an annual rate just below the Fed’s 2.0% goal.
The Fed’s preferred CPI number is Core CPI Services excluding shelter. It was down 0.001% in June.
Click for larger graphic h/t @MacroAlf
Today’s Producer Price Index was up only +0.1% from last year – virtually unchanged, and below the +0.4% estimate. The PPI was +11.2% just a year ago due to supply chain snarls and is about to enter deflation. The Core PPI was up +2.4%, below the +2.8% estimate. On a month-over-month basis, both measures were +0.1%.
Treasury yields dropped sharply after the report, yet the CME FedWatch Tool still shows institutions are 94.9% sure of a 25 basis point increase at the July 26 meeting.
Hmm, let’s recap. A below-consensus nonfarm payrolls report for the first time in 15 months, a below-consensus CPI, and a below-consensus PPI, yet there is no belief that the Fed’s pause will continue? I’m 94.9% sure they are wrong.
Market Outlook
The S&P 500 added 2.2% since last Thursday, setting new 52-week intraday and closing highs today. The Index is up 17.5% year-to-date. The Nasdaq Composite gained 4.1% in spit of the coming Nasdaq 100 “Special Rebalancing.” It is up a whopping 35.1% for the year. The small-cap Russell 2000 finally caught fire, soaring 5.9% to be up 10.8% in 2023.
I wrote last week that: “The fractal dimension didn’t move much in this nothing burger week, so we still are in rally mode. Let’s see what tomorrow’s payrolls and next week’s CPI do.” So now we know. The fractal dimension is firmly in rally mode with enough energy to continue for another two to four weeks before the inevitable and healthy consolidation.
The major fly in the ointment – and it’s a pretty big fly – is that almost everyone is on board and fully invested.
Click for larger graphic
Top 5
Changes this week: Added FCX to Near-Term
Near-Term – chronological order
EQT EQT –natural gas price rebound
USL United States 12 Month Oil Fund, LP – crude should rise quickly
FCX Freeport McMoRan – copper shortage this fall
SFTBY SoftBank – for ARM IPO this fall
AKBA Akebia – Vadadustat NDA filing 2023; approval 2024
VLD Velo3D – Rapid revenue growth; low market cap
Long-Term – alphabetical order
EQT EQT – largest US natural gas company
NVTA Invitae – the winner-take-most of genetic testing
META Meta – a (the?) leader in the metaverse
RKLB Rocket Lab – #2 to SpaceX in space
VLD Velo3D – Return manufacturing to the US
GBTC Grayscale Bitcoin Trust – Bitcoin is headed for $100,000
Economy
The Atlanta Fed’s GDPNow model increased from +2.1% to +2.3% as real gross private domestic investment growth strengthened.
Click for larger graphic
The ratio of US household liabilities to net worth is down to 13.05%, the lowest since the early 1980s.
Click for larger graphic h/t @WallStJesus
Coming Events
All times below are ET, and most presentations and slides are archived on the companies’ websites so you can listen to them.
Friday, July 14
Happy Bastille Day! (markets open)
Wednesday, July 19
GRPH – Graphite Bio – 11:00am – Annual meeting
Thursday, July 20
FCX – Freeport McMoRan – 10:00am – Earnings conference call
Big Tech: The Biotech & Digital Dominators MegaShift
There are at least four ways to make money in the stocks of these large, growing, dominant companies. You can:
* * Buy a stock and hold it
* * Buy a stock and write a call option against it
* * With a Level IV options account, write an out-of-the-money put option
* * With a Level IV options account, write an out-of-the-money put option and use part of the premium to buy an out-of-the-money call option
Apple (AAPL – $190.54) got a $200 target price from Keybank, with an Overweight rating. At about $190.75 Apple has a $3 trillion market capitalization. They said data from more than 1.8 million unique KeyBanc credit and debit card customers in the US showed spending on Apple transactions of $400 or more jumped 23% month over month in June.
But the data show a -15% slide quarter over quarter, which is worse than the three-year historical average of a 9% decline in the three months to the end of June. Even so, they said: “We believe the bull case for the stock with excitement around new products and investors reaching for safety is resulting in an elevated multiple.”
Well, yeah. That’s why we own the stock. But it’s also why I haven’t raised the buy limit. Everyone knows the iPhone 15 is coming in September, but no one knows how well it will sell. One bad month in the market – say, August – combined with conservative September quarter guidance and a few Wall Street downgrades to write some trade tickets easily could put Apple under my buy limit. AAPL is a Buy under $150 for new iPhone rollouts and augmented/virtual reality products.
Meta Platforms (META – $313.41) new Twitter competitor, Threads, hit 100 million users in five days, making it the fastest-growing consumer application in history. Threads trounced ChatGPT’s record, which achieved the milestone in two months.
Today, TD Cowen upgraded the stock from market perform to outperform and raised their target price from $220 to $345, citing positive checks for the June quarter and the potential for further market share gains. They wrote: “TD Cowen Proprietary 2Q23 Social Survey Data through June ’23 shows modest [year-over-year] engagement improvement at Instagram and Core Facebook. Respondents once again indicated rising usage of IG Reels, suggesting that Reels could be a driver of incremental time spent on Instagram.”
They said their June quarter digital ad check was “positive” for Meta and suggested further monetization of Reels via image-based overlay ads that launched on Instagram at the end of June. They expect June quarter and 2023 revenue and earnings to be above Wall Street estimates. They raised their revenue and earnings estimates for the next five years by 8% and 7% and said that there is the potential for more cost cuts. They concluded: “We do not have any potential Threads revenue in our current Meta forecast, but if the service attracts further users and engagement, we expect Meta to start to monetize the app,” probably by bringing Instagram’s branded content tools to Threads. META is a Buy under $150 for a $400 target in 2024.
Small Tech
Rocket Lab USA (RKLB – $6.64) will launch seven satellites for NASA from Launch Complex 1 in New Zealand during a launch window that opens July 14. It will be their 39th Electron launch.
Today they announced a deal with Japanese earth imaging company Synspective to launch two more dedicated Electron missions. Rocket Lab has been launching for Synspective since 2020, when they deployed the first satellite in Synspective’s synthetic aperture radar (SAR) constellation. It is designed to deliver imagery that can detect millimeter-level changes to the Earth’s surface from space. Since that first mission, Rocket Lab has been the sole launch provider for Synspective, successfully deploying three StriX satellites in three dedicated Electron launches. Including the two new missions, Rocket Lab is now scheduled to launch three missions for Synspective beginning in late 2023. RKLB is a Buy up to $13 for my $30+ target as low earth orbit satellites and space exploration grow.
Primary Risk: A new competitor emerges.
Biotech MegaShift: The $20-For-$1 Stocks
Say you put $2,000 into a stock that goes from 50¢ a share to $10. The $2,000 turns into $40,000. Then you put the $40,000 into another stock that goes from 50¢ to $10. That turns the $40,000 into $800,000. You did it with two stocks and never risked going negative more than $2,000. (Not that you won’t be mad at me if the first one works and then the second one doesn’t, taking your $40,000 to Money Heaven.)
If you can afford it – and it would not be too big a position in your portfolio – putting $2,000 into each of these speculative biotechs might be a good way to start. Buying these out-of-favor, fallen, or forgotten companies that can get important products through the FDA at very low market capitalizations seems like a good strategy to me.
Risks
Development-stage biotechs are subject to investor sentiment swings from wildly optimistic to excessively pessimistic – mostly the latter recently. After the Primary Risk for each company, I’ve added the clinical stage of their lead product, the probable time of their first FDA approval, and the probable time of their next financing.
As always, you need to think about an appropriate position size. You could buy a full position upfront and then just hold on, or buy some upfront and leave room to add more on the inevitable financings, transient clinical trial setbacks, and the like.
Compass Pathways (CMPS – $9.53) posted a new presentation that highlighted their digital tools.
Click for larger graphic
Click for larger graphic
CMPS is a Buy under $20 for a very long-term hold to a 10x.
Primary Risk: Their drugs fail in the clinic.
Clinical stage of lead product: Phase 2
Probable time of first FDA approval: 2025
Probable time of next financing: Late 2023
Graphite Bio (GRPH – $2.63) holds their annual meeting next Wednesday and should reveal their path forward. GRPH is a Hold until the conference call.
Primary Risk: Their drugs fail in the clinic.
Clinical stage of lead product: Pre-clinical
Probable time of first FDA approval: Unknown
Probable time of next financing: Unknown
TG Therapeutics (TGTX – $21.75) dropped 14.6% today after Genentech, a Roche subsidiary, reported successful Phase 3 results for their Ocrevus multiple sclerosis therapy as a twice-a-year 10-minute subcutaneous (SC) injection against Ocrevus given by intravenous infusion.
TG’s big selling point is their one-hour infusion following initial dosing. But the Genentech Phase 3 only showed comparable efficacy at 12 weeks, so I want to see the six-month follow-up data. Hold TGTX for a target price in a buyout of $25 or more now that the MS drug is approved.
Primary Risk:Briumvi, the MS drug, fails to sell.
Clinical stage of lead product: Approved
Probable time of next FDA approval: NM
Probable time of next financing: Second half of 2023
Inflation MegaShift
Gold ($1,964.80) may have broken out of its trading range today. As you’ve probably noticed, low inflation numbers make gold go up because it means less Fed pressure on interest rates and therefore a weaker dollar. That’s ass-backwards from the way gold acted before we had such an activist Fed, but it is what it is.
If we get a higher inflation print than expected (or a stronger labor number), markets will immediately fear the Fed’s higher rates and mark gold down (and the dollar up). So, low inflation = strong gold and high inflation = weak gold – until it doesn’t.
Last week I wrote: “Gold is stuck in a tight $1,900 to $1,935 trading range, causing the fractal dimension to barely stay in trend mode. Another down week would abort the trend and send gold back into consolidation.” Gold had a good week and the fractal dimension remains in a trend with room to run higher.
Cryptocurrencies
Cryptocurrencies are a diversifying asset that offer a unique opportunity to make (or lose!) a lot of money quickly. You can easily buy bitcoin and other cryptocurrencies at Coinbase, Block, or Robinhood.
Bitcoin (BTC-USD on Yahoo – $31,498.15) broke out higher today, in part due to a sharp rally in Litecoin attributed to an upcoming halving (bitcoin’s halving is next Spring) and mostly due to institutional investors putting half a billion dollars worth of assets into digital asset investment products—mostly ones that hold bitcoin—in the last three week
According to a recent report by CoinShares, digital asset investment products registered $136 million in inflows in the past seven days, bringing the three-week total to $470 million. This eclipses the previous nine weeks of outflows, bringing year-to-date flows to a bullish +$231 million.
Click for larger graphic
BTC-USD, ETH-USD, GBTC, and ETHE are Strong Buys.
Primary Risk: Bitcoin falls due to over-regulation or is surpassed by another cryptocurrency.
Grayscale Bitcoin Trust (GBTC- $21.38) has nearly tripled in the last six months, but it’s still selling at a 24.4% discount to net asset value. The narrowing of the discount from the mid- to high-40% area has been very enjoyable, and there’s more to come.
Grayscale’s lawyer just submitted a letter to the judge in their case about the Volatility Shares Trust – 2x Bitcoin Strategy ETF (BITX) being approved and how that just adds to their case about how can that exist and not a vanilla spot ETF?
Click for larger graphic
GBTC is a Buy under net asset value.
Primary Risk: Bitcoin falls due to over-regulation or is surpassed by another cryptocurrency.
Commodities
Oil – $77.28
Oil moved up sharply as the paper oil traders suddenly realized supplies are falling while demand is increasing. (See this SeekingAlpha article: Oil Is Asymmetrically Positioned To The Upside.) Only 0.4 million barrels of crude were released from the Strategic Petroleum Reserve for the week ending July 7. We are done with SPR releases, as all 26 million barrels that were planned to be released are now released.
Click for larger graphic
The July 2026 Crude Oil Futures (CLN26.NYM – $64.91) are a Buy under $65 for a $200+ target. Only buy futures for all cash; do not use margin. You can buy them on the New York Mercantile Exchange.
The United States 12 Month Oil Fund, LP (USL – $35.20) is a Buy under $35 for a $100+ target.
Freeport McMoRan (FCX – $42.08) got an upgrade to its relative strength rating from 70 to 75 by Investor’s Business Daily, which told their legion of subscribers to buy the stock when it goes over $46.73. Given the fact that the world is running out of copper inventories, I expect that to happen sooner rather than later.
The company reports earnings next Thursday morning. Analysts are expecting $5.52 billion in revenues, 1.9% above last year, with 34¢ earnings per share. The September quarter guidance consensus is $5.51 billion and 39¢. I added FCX to the Near-Term buys for the copper shortage this fall. FCX is a buy under $44 for a $65 target within two years.
Primary Risk: Copper prices fall.
* * * * *
Click for larger graphic
* * * * *
Your trying bionic reading Editor,
Michael Murphy CFA
Founding Editor
New World Investor
All Recommendations
Check out the complete Portfolio page HERE.
Buys
These are the stocks everyone needs to own because transformative events are happening over the next year or two, and I expect to hold them long-term.
Tech Dominators
Apple Computer (AAPL – $190.54) – Buy under $150 for new iPhones
Corning (GLW – $35.82) – Buy under $33, target price $60
Gilead Sciences (GILD – $76.71) – Buy under $80, target price $120
Meta (META – $313.41) – Buy under $250, target price $400
SoftBank (SFTBY – $25.99) – Buy under $25, target price $50
Small Tech
Enovix (ENVX – $20.77) – Buy under $13; 4-year hold to $100+
First Trust NASDAQ Cybersecurity ETF (CIBR – $45.92) – Buy under $40; 3- to 5-year hold
Fastly (FSLY – $18.18) – Buy under $20; 2- to 5-year hold to $80+
PagerDuty (PD – $24.70) – Buy under $30; 2- to 5-year hold
QuickLogic (QUIK – $8.91) – Buy under $10, target price $40
Rocket Lab (RKLB – $6.64) – Buy under $13, target price $30+
Velo3D (VLD – $2.24) – Buy under $6, target price $50
$20-for-$1
Akebia Biotherapeutics (AKBA – $1.09) – Buy under $2, target $20
Aptose Biosciences (APTO – $4.44) – Buy under $10, ultimate target $300
Compass Pathways (CMPS – $9.53) – Buy under $20, hold a long time for a 10x return
Inovio (INO – $0.56) – Buy under $7, hold a long time
Invitae (NVTA – $1.30) – Buy under $10, first target $50, then $100+
Medicenna (MDNA – $0.49) – Buy under $3, first target $20, then maybe $40
ScyNexis (SCYX – $2.74) – Buy under $2.50, target price $20, then $50
Inflation
A Short-Sale or REO House – ($447,000) – Hold
Bag of Junk Silver – ($25.10) – hold through silver bull market
Sprott Gold Miners ETF (SGDM – $27.37) – Buy under $28, target price $50
Sprott Junior Gold Miners ETF (SGDJ – $31.75) – Buy under $39, target price $100
Sprott Physical Gold and Silver Trust (CEF – $18.60) – Buy under $18, target price $30
Global X Silver Miners ETF (SIL – $27.64) – Buy under $30, target price $50
Coeur Mining (CDE – $3.07) – Buy under $5, target price $20
First Majestic Mining (AG – $6.44) – Buy under $11, next target price $23
Paramount Gold Nevada (PZG – $0.33) – Buy under $1, first target price $10
Sandstorm Gold (SAND – $5.57) – Buy under $10, target price $25
Sprott Inc. (SII – $34.02) – Buy under $40, target price $70
Cryptocurrencies
Bitcoin (BTC-USD – $31,498.15) – Buy
Grayscale Bitcoin Trust (GBTC – $21.38) – Buy
Ethereum (ETH-USD – $1,983.12) – Buy
Grayscale Ethereum Trust (ETHE – $12.06) – Buy
Commodities
Crude Oil Futures – July 2026 (CLN26.NYM – $64.91) – Buy under $65; $200+ target
United States 12 Month Oil Fund, LP (USL – $35.20) – Buy under $35; $100+ target
EQT (EQT – $39.41) – Buy under $35; $70 first target
Energy Fuels (UUUU – $6.36) – Buy under $8; $30 target
Freeport McMoRan (FCX – $42.08) – Buy under $44; $65 target within two years
International & Other Recommendations
EMQQ Emerging Markets Internet & Ecommerce ETF (EMQQ – $32.02) – Buy under $38 for a $66 target in 12 to 18 months
KraneShares Bosera MSCI China A Share Fund (KBA – $24.25) – Buy under $40 for a three- to five-year hold
Morgan Stanley China A-Shares Fund (CAF – $12.94) – Buy under $18 for a three- to five-year hold
KraneShares CSI China Internet ETF (KWEB – $30.15) – Buy under $40 for a double over the next three years
Acreage Holdings (ACRDF – $0.24) – Buy under $2 for the Canopy Growth merger
Mongolia Growth Group (MNGGF – $0.89) – Buy under $1.30; long-term hold
Holds
These are holds but not sells – yet. They could get moved back to one of the buy categories if their prices drop or outlook improves, or they could become sell recommendations in the future.
Arch Therapeutics (ARTH – $2.85) – Hold for buyout
Graphite Bio (GRPH – $2.63) – Hold until they update their strategy
TG Therapeutics (TGTX – $21.75) – Hold for buyout at $25+
Publisher: GwynRose LLC, 5348 Vegas Drive, Suite 868, Las Vegas, NV 89108
New World Investor does not act as a personal investment adviser or advocate the purchase or sale of any security or investment for any specific individual. The recommendations and analysis presented to members are for the exclusive use of members. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. Likewise, past performance does not assure future results. Recommendations are subject to change at any time. Nothing in this presentation should be considered personalized investment advice. No communication to you by Michael Murphy or any of our employees or contractors should be deemed as personalized investment advice.
Copyright ©GwynRoseLLC 2023
New World Investor Mastermind Group
1. Post unto others as you would have them post unto you.
2. Keep it clean, like a 1950s family television show. Your alter ego can run free on Twitter.
3. NO PERSONAL ATTACKS! If you don’t like the stock, don’t trash the person. Everyone is responsible for their own due diligence and investments.
4. Don’t post here about politics or religion – you aren’t going to change anyone’s mind. Again, NO PERSONAL ATTACKS!
5. The investment implications of something going on in politics or religion is OK.
6. Of course, there’s never a reason to slur someone based on race, religion, gender, sexual orientation, or country of national origin.
7. Please, no snark!
Print This Post
First!
MM
What!?
No comment on NVTA.
My biggest position
No news in two months
A pivotal Quarter about to report
Expectations for earnings, guidance, stock price
Something, please.
NVTA- Down 98+% from the high at $60, every article on SA is neutral or bearish, large short position. Unless they have sold recently both Cathy Woods and Baker Brothers are very large investors. IF it survives, it will make you a ton of money as simple mean reversion will bounce it 5-10x minimum.
Trading above the 50MA a positive.
Thanks for that
All that you stated are the reasons for holding
Still I would like the one who recommended it to add something of value
LOL, LOL. Will ARTH revert to the mean and offer a 5-10x return from recent prices? AC5 is a superior product, but NVTA offers merely a supermarket reseller/recycler of genetic tests available through established sources. Compared to NVTA, I consider ARTH a Berkshire Hathaway of its product. This is the theater of the absurd from our schoolboy days. Thanks for the comedy relief. You’re Act 1, I’m Act 2.
JGMD – I’m holding a big bag of ARTH, are you saying that there’s a good possibility it will 5-10X?
I waited and waited for AC5 sales to come, but they never did, so I sold almost a year ago. More prudent subscribers like Chris sold many years ago with less losses and maybe some trading profits. With still near zero sales, I say ARTH will completely wipe out retail investors. My message above is that AC5 is a superior product of its kind, whereas NVTA offers tests that can be obtained elsewhere. Genetic tests are utilized for a small fraction of patients, and the revenue cannot rise to make that company profitable. The tragedy is that superior products like AC5 are often failures in the marketplace.
Famous musical tragedies include the lives of Schubert and Mozart. Schubert was recognized as a genius by only his small circle of friends, and he died in poverty. Mozart achieved much greater fame in his lifetime, but he too died poor. Today, 200 years later, both Schubert and Mozart musical works are widely performed and make lots of money from public concerts and recordings. They will continued to be performed 500 years from now, but there are no estates of either composer to collect royalties. NVTA and ARTH will be buried in the ground, just like the bodies of Schubert and Mozart.
“whereas NVTA offers tests that can be obtained elsewhere at higher prices with slower turnaround”
fixed it for you
Today Show yesterday. Segment on genetic testing for cancer.
Get Informed:
I hope that by starting this conversation, we can make a difference together. According to a 2016 study that Dr. Port told me about, there’s now a term known as the Angelina Jolie Effect. When Jolie announced she was getting preventative surgery in 2013 after losing her mother to breast and ovarian cancer and testing positive for the BRCA gene, the number of people who went and got tested in the next six months increased by 105%, according to the study. In addition, the number of people discovered to actually have the gene mutation among those who got tested also doubled.
Do you know how many lives she likely helped save? My guess is a lot.
:/
Many more lives would be saved from paying attention to obesity and other aspects of nutrition, stopping smoking/alcohol than from ANY testing. Suppose you get a mammogram and colonoscopy every month to detect these common cancers as early as possible. But most people are overweight and lots are obese and are uninformed about the benefits of higher vitamin D levels. Correction of bad lifestyle and nutritional deficiencies saves more lives than does testing. A rich person could pay out of his pocket for all this testing, but this literal fat cat would benefit more from what I mentioned.
The number of purely genetic caused cancers is a small percentage compared to the number of cancers caused by bad lifestyle. You could have good genes, but the expression of them is mainly dependent on lifestyle and nutritional care. Good genes and bad lifestyle cause most cancers. The expression (phenotype) is the final determinant of cancer risk and prognosis, not the raw gene data (genotype). If a person has optimized their lifestyle and nutrition, they could still get cancer with unfavorable genotype, but this is a small fraction of the total cancer incidence.
People don’t want to hear the truth, but want the magic bullet assurance that if they have the right genes, they are protected from cancer. Then there’s the prognosis. Obese people and low vitamin D levels will make for a worse prognosis. A low carb/keto diet improves survival times, but I have seen ignorant nutrition departments at prestigious hospitals who institute medium/high carb diets which worsen prognosis. I knew a patient who couldn’t eat get Jevity, a high carb liquid feeding from Big Pharma Abbott. Stupid.
Also, let’s assume a woman follows Angelina Jolie’s advice and gets the double mastectomy after confirmed BRCA mutations. She saves herself from breast cancer. But she doesn’t eliminate the cancer risk from unhealthy lifestyle and nutrition. She can do genetic testing for many cancers, and remove all the organs associated with those genes. Or, she can prevent hundreds of diseases with one decision to reform her bad general health and preserve all her body parts. Bad general health is inflammatory, which causes most cancers, vascular disease, most neurologic diseases, GI disorders, etc.
Recurrent vaginal yeast infections are due to a bad diet with sugar. This is why SCYX’s new drugs have only a mediocre benefit over cheap azole generics. A person will accomplish much more with a healthy diet/lifestyle instead of a diet of more drugs with toxic side effects, or more surgery, chemo, radiation, etc.
In the June 8 Radar Report, I showed the steady, dramatic improvement in the cash burn. I expect that to continue in the June quarter to under $50 million. That’s the main thing Wall Street needs to see.
The estimate is revenues are down 12% from last year due to discontinued businesses and a 37¢ loss, much better than last year’s 68¢ loss. Seems like a pretty low hurdle.
MM Thank you!
We should expect another market beat?
Do you think recognition of a turnaround to be reflected in the stock price. This has not happened to date and could lead to a short squeeze leading to a more accurate value.
MM – I want to be sure what you are saying – did you split away the biotech moonshots to a separate newsletter and do we need another subscription to access that newsletter?
I’ll cover the bio moonshots in both newsletters, so no separate subscription needed.
Boomberg does have 5 additional Big Tech recommendations that are not in New World Investor.
Michael – I know you store your bitcoin on a cold storage wallet, what platform do you use to trade or exchange bitcoin for USD from the cold wallet to minimize fees?
TGTX–read the excellent informative YMB posts of Axel. Roche’s subcu version of Ocrevus is inferior in every way to TGTX’s Briumvi. The only advantage of Ocrevus is the marketing muscle of Roche which can dress up a pig to draw attention away from Briumvi.
Totally agree
Also, Axel says that subcu Ocrevus (O) will actually be more costly than intravenous (IV) O, due to the extra work in getting the large volume in the subcu space and separating the subcu layers. Normally subcu injections are much easier than IV injections, as with the Epipen which can be given by anyone in an emergency. But subcu O is actually more labor and time intensive than IV O. Roche fooled the market and even me at first, until Axel pointed this out.
This reply is to Gary on 7/6/23 RR. Yes FED NOW is the new crypto that the government is coming out with. I also bought XLM (last couple of weeks) currently up $250 ish. The word I am getting is Bitcoin is going to break out soon.
UUUU is not just a nuke holding. It is also pushing into rare earths. It acquired 17 rare earth mineral projects in Brazil. And Biden is pouring $$$$$$ into rare earth companies that are NOT in China. Just FYI
OPTT up sharply today on increased volume, cup and handle pattern.
glta.
Too bad I gave up on it about 10 years ago.
Looks like this is driving down QUIK today.
QuickLogic Stock: Avoid, For Now, A Financial Overview (NASDAQ:QUIK) | Seeking Alpha
This article describes the reasons behind my suffering in QUIK for about a decade. It all depends on when they report sustained profits and stop diluting.
MM?
The new Radar Report for 7.20.23 is posted. I raised my estimate of the TGTX buyout price to $30+.